Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 25 January

Sam Kanaan
January 25, 2024

Morning Bell 24 January

Grady Wulff
January 24, 2024

Morning Bell 23 January

Grady Wulff
January 23, 2024

Morning Bell 22 January

Grady Wulff
January 22, 2024

Weekly Wrap 19 January

Sophia Mavridis
January 19, 2024

Morning Bell 19 January

Sam Kanaan
January 19, 2024

Morning Bell 18 January

Grady Wulff
January 18, 2024

Morning Bell 17 January

Grady Wulff
January 17, 2024

Morning Bell 16 January

Grady Wulff
January 16, 2024

Morning Bell 15 January

Sophia Mavridis
January 15, 2024

Weekly Wrap 15 December

Grady Wulff
December 15, 2023